Floatz logo

Galantamine Hydrobromide

Dementia

Janssen Pharmaceutica N.V., BelgiumUNKNOWNPhase 3Dormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
81/ 100

Competitive context

43 Active assets in the Dementia cohort.

Asset / SponsorPhaseRating
Risperidone
Hannover Medical School
Phase 4BBB
CITALOPRAM
Hannover Medical School
Phase 4BBB
Escitalopram
Ohio State University
Phase 4BB
Memantine
Zealand University Hospital
Phase 4BB
Ioflupane
Mayo Clinic
Phase 4BB

View all 50 →

Same molecule, other indications

Galantamine Hydrobromide is also rated in:

Alzheimer diseaseDormant
BBB
Indicative · Phase 4
72 / 100
View asset →
mental disorderDormant
BB
Indicative · Phase 3
66 / 100
View asset →
vascular dementiaDormant
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →